UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

CPT: pharmacometrics and systems pharmacology, 2024-03, Vol.13 (3), p.494-503

2024

Volltextzugriff (PDF)

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell metabolism, 2022-09, Vol.34 (9), p.1234-1247.e9

2022

Volltextzugriff (PDF)

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

European journal of cancer (1990), 2014-02, Vol.50 (3), p.486-495

2014

Volltextzugriff (PDF)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1886-1891

2020

Volltextzugriff (PDF)

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Journal of pharmaceutical sciences, 2010-03, Vol.99 (3), p.1582-1600

2010

Volltextzugriff (PDF)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI insight, 2020-09, Vol.5 (17)

2020

Volltextzugriff (PDF)

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-03, Vol.877 (8), p.837-841

2009

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.1049-1059

2021

Volltextzugriff (PDF)

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

mAbs, 2010-01, Vol.2 (1), p.67-72

2010

Volltextzugriff (PDF)

Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys

European journal of pharmaceutical sciences, 2024-11, Vol.202, p.106895, Article 106895

2024

Volltextzugriff (PDF)

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Volltextzugriff (PDF)

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

Diabetes, obesity & metabolism, 2022-02, Vol.24 (2), p.239-246

2022

Volltextzugriff (PDF)

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Volltextzugriff (PDF)

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

The Lancet (British edition), 2022-11, Vol.400 (10366), p.1869-1881

2022

Volltextzugriff (PDF)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2022-07, Vol.61 (7), p.1057-1067

2022

Volltextzugriff (PDF)

971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Current medical research and opinion, 2024-04, Vol.40 (4), p.567-574

2024

Volltextzugriff (PDF)

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

Journal of immunoassay & immunochemistry, 2009-10, Vol.30 (4), p.418-427

2009

Volltextzugriff (PDF)

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Diabetes care, 2023-05, Vol.46 (5), p.998-1004

2023

Volltextzugriff (PDF)

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

The journal of clinical endocrinology and metabolism, 2024-01, Vol.109 (2), p.361-369

2024

Volltextzugriff (PDF)

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

The journal of clinical endocrinology and metabolism, 2024-05

2024

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(44)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Diabetes
(18)
Antidiabetics
(15)
Glucagon
(15)
Pharmacokinetics
(14)
Diabetes Mellitus
(12)
Humans
(12)
Diabetes Mellitus, Type 2 - Drug Therapy
(9)
Weight Control
(9)
Body Weight
(8)
Endocrinology & Metabolism
(8)
Polypeptides
(8)
Type 2 Diabetes
(8)
Body Weight Loss
(7)
Pharmacology & Pharmacy
(7)
Safety
(7)
Agonists
(6)
Animals
(6)
Clinical Trials
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

Aktive Filter

Suchergebnisse filtern